601 related articles for article (PubMed ID: 34137513)
1. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ; Chen JX; Sun ZJ
Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
[TBL] [Abstract][Full Text] [Related]
2. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.
Zhu N; Weng S; Wang J; Chen J; Yu L; Fang X; Yuan Y
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3021-3036. PubMed ID: 31617075
[TBL] [Abstract][Full Text] [Related]
3. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
Leong A; Kim M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.
Xue L; Gao X; Zhang H; Tang J; Wang Q; Li F; Li X; Yu X; Lu Z; Huang Y; Tang R; Yang W
BMC Cancer; 2021 Oct; 21(1):1134. PubMed ID: 34686154
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.
Kuo HY; Khan KA; Kerbel RS
Nat Rev Clin Oncol; 2024 Jun; 21(6):468-482. PubMed ID: 38600370
[TBL] [Abstract][Full Text] [Related]
7. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
Melaiu O; Vanni G; Portarena I; Pistolese CA; Anemona L; Pomella S; Bei R; Buonomo OC; Roselli M; Mauriello A; Barillari G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834641
[TBL] [Abstract][Full Text] [Related]
8. Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications.
Zhou S; Zhang H
Anticancer Agents Med Chem; 2020; 20(7):768-776. PubMed ID: 32031076
[TBL] [Abstract][Full Text] [Related]
9. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
10. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Lee WS; Yang H; Chon HJ; Kim C
Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
[TBL] [Abstract][Full Text] [Related]
11. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF Treatment Enhances CD8
de Almeida PE; Mak J; Hernandez G; Jesudason R; Herault A; Javinal V; Borneo J; Kim JM; Walsh KB
Cancer Immunol Res; 2020 Jun; 8(6):806-818. PubMed ID: 32238381
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
14. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.
Ren S; Xiong X; You H; Shen J; Zhou P
Front Immunol; 2021; 12():689132. PubMed ID: 34149730
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
18. Combining microenvironment normalization strategies to improve cancer immunotherapy.
Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113
[TBL] [Abstract][Full Text] [Related]
19. Combinations of Bevacizumab With Cancer Immunotherapy.
Chen DS; Hurwitz H
Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
[TBL] [Abstract][Full Text] [Related]
20. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
Wachsberger P; Burd R; Dicker AP
Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]